Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Study of Nusinersen in Spinal Muscular Atrophy Patients Previously Treated with Onasemnogene Abeparvovec
2020-003492-18Phase 4Active
- Sponsor
- Biogen
- Start
- Mar 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoint: Total HINE Section 2 Motor Milestones Score. Started Mar 2021; status: active.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2020-003492-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003492-18.